Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context

被引：11

作者：

Hoffman-Censits, Jean ^{[1
,2
,4
,5
]}

Maldonado, Laneisha ^{[3
]}

机构：

[1] Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Med Oncol, Baltimore, MD USA

[2] Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Urol, Baltimore, MD USA

[3] Johns Hopkins Univ, Dept Med, Baltimore, MD USA

[4] Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Med Oncol, 201 N Broadway 9th Floor, Baltimore, MD 21287 USA

[5] Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Urol, 201 N Broadway 9th Floor, Baltimore, MD 21287 USA

来源：

ONCOTARGETS AND THERAPY | 2022年 / 15卷

关键词：

antibody-drug conjugate; urothelial cancer; metastatic; treatment refractory; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; OPEN-LABEL; CARCINOMA; CHEMOTHERAPY; MULTICENTER; PEMBROLIZUMAB; NECTIN-4; THERAPY; TRIAL;

D O I：

10.2147/OTT.S370900

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Enfortumab vedotin (EV) is a novel antibody-drug conjugate that is the first in class to be FDA-approved for use in patients with treatment-refractory urothelial cancer. Enfortumab is comprised of an antibody targeting nectin-4, widely expressed in urothelial cancers, with an monomethyl auristatin E (MMAE) chemotherapy payload. To date, trials in urothelial cancers refractory to platinum-based chemotherapy, and or checkpoint inhibitors, have shown the drug is very active, with overall responses ranging from 40% to 52%. This includes patients with visceral metastasis, a known predictor of poor prognosis. EV is fairly well tolerated, including in patients who are not candidates for cisplatin, a common urothelial cancer population with significant unmet need. Side effects such as skin toxicity, fatigue, and blood sugar elevations are generally manageable with supportive care and dose modifications. Peripheral neuropathy is common and can be dose-limiting in responding patients, and rare serious skin toxicities have been reported. Trials in various disease states and in combination with checkpoint inhibitors and other agents are ongoing, with additional indications likely in the future for EV in urothelial cancer.

引用

页码：1519 / 1529

页数：11

共 41 条

[1] FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma [J].

Adib, Elio ;

El-Zarif, Talal ;

Jain, Rohit K. ;

Skelton, William P., IV ;

Freeman, Dory ;

Curran, Catherine ;

Akl, Elie W. ;

Nassar, Amin H. ;

Ravi, Praful ;

Mantia, Charlene ;

Kwiatkowski, David J. ;

Choueiri, Toni K. ;

Sonpavde, Guru P. .

BJUI COMPASS, 2022, 3 (02) :169-172

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. [J].

Balar, Arjun Vasant ;

McGregor, Bradley Alexander ;

Rosenberg, Jonathan E. ;

van der Heijden, Michiel Simon ;

Park, Se Hoon ;

Lee, Jae-Lyun ;

Harrison, Michael Roger ;

Heath, Elisabeth, I ;

Stein, Mark N. ;

Loriot, Yohann ;

Necchi, Andrea ;

Steinberg, Joyce Leta ;

Liang Shang-Ying ;

Kim, Eric ;

Trowbridge, Janet ;

Campbell, Mary S. ;

Petrylak, Daniel Peter ;

Yu, Evan Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[5] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[6] Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate [J].

Cabaud, Olivier ;

Berger, Ludovic ;

Crompot, Emerence ;

Adelaide, Jose ;

Finetti, Pascal ;

Garnier, Severine ;

Guille, Arnaud ;

Carbuccia, Nadine ;

Farina, Anne ;

Agavnian, Emilie ;

Chaffanet, Max ;

Goncalves, Anthony ;

Charafe-Jauffret, Emmanuelle ;

Mamessier, Emilie ;

Birnbaum, Daniel ;

Bertucci, Francois ;

Lopez, Marc .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (07) :1227-1235

[7] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models [J].

Challita-Eid, Pia M. ;

Satpayev, Daulet ;

Yang, Peng ;

An, Zili ;

Morrison, Karen ;

Shostak, Yuriy ;

Raitano, Arthur ;

Nadell, Rossana ;

Liu, Wendy ;

Lortie, Dawn Ratay ;

Capo, Linnette ;

Verlinsky, Alla ;

Leavitt, Monica ;

Malik, Faisal ;

Avina, Hector ;

Guevara, Claudia I. ;

Dinh, Nick ;

Karki, Sher ;

Anand, Banmeet S. ;

Pereira, Daniel S. ;

Joseph, Ingrid B. J. ;

Donate, Fernando ;

Morrison, Kendall ;

Stover, David R. .

CANCER RESEARCH, 2016, 76 (10) :3003-3013

[8] A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads [J].

Chia, C. S. Brian .

CHEMMEDCHEM, 2022, 17 (11)

[9] Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. [J].

Chu, Carissa ;

Sjostrom, Martin ;

Egusa, Emily A. ;

Gibb, Ewan ;

Badura, Michelle L. ;

Koshkin, Vadim S. ;

Stohr, Bradley A. ;

Meng, Maxwell ;

Pruthi, Raj ;

Friedlander, Terence W. ;

Lotan, Yair ;

Black, Peter C. ;

Porten, Sima P. ;

Feng, Felix Y. ;

Chou, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[10] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 [J].

De Santis, Maria ;

Bellmunt, Joaquim ;

Mead, Graham ;

Kerst, J. Martijn ;

Leahy, Michael ;

Maroto, Pablo ;

Gil, Thierry ;

Marreaud, Sandrine ;

Daugaard, Gedske ;

Skoneczna, Iwona ;

Collette, Sandra ;

Lorent, Julie ;

de Wit, Ronald ;

Sylvester, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) :191-199

← 1 2 3 4 5 →